Dissociative anesthetics are a class of drugs that produce unconsciousness, pain relief, and amnesia by blocking a specific type of receptor in the brain called the NMDA receptor, which normally responds to the signaling chemical glutamate. The term “dissociative” was coined in the 1960s to describe the peculiar trance-like state these drugs create: patients appear disconnected from their environment and their own bodies, yet unlike people under conventional anesthesia, they often keep breathing on their own and maintain stable blood pressure. Ketamine and phencyclidine (PCP) are the two best-known members of this class, and their unusual pharmacology has made them among the most versatile and controversial drugs in medicine.
Where the Class Came From
The story starts in 1956, when a chemist named Maddox first synthesized phencyclidine. Animal studies followed quickly, and by 1958 the first human trials of PCP were underway under the brand name Sernyl. The drug worked as an anesthetic, but it came with a serious drawback: patients emerging from PCP anesthesia experienced severe agitation and prolonged, disorienting recovery periods. Those same psychoactive properties eventually made PCP attractive as a street drug, where it became known as “angel dust.”1Annales Medico-Psychologiques. A story of ketamine and psychedelics
Researchers wanted the anesthetic benefits without the wild emergence reactions, so chemist Calvin Stevens synthesized ketamine in 1962 as a shorter-acting, less potent relative of PCP. When Edward Domino and Guenter Corssen tested it in humans two years later, they found that patients entered an unusual state they called “dissociative anesthesia,” a term that stuck and eventually named the entire drug class.1Annales Medico-Psychologiques. A story of ketamine and psychedelics Ketamine went on to become one of the most widely used anesthetics in the world, listed on the World Health Organization’s Model List of Essential Medicines. PCP, meanwhile, largely disappeared from clinical use but never left the illicit market.
The NMDA Receptor and the Core Mechanism
To understand how dissociative anesthetics work, you need to know a little about the NMDA receptor. It sits on the surface of neurons throughout the brain and spinal cord and acts as a gate for electrically charged particles. When the signaling molecule glutamate binds to it, the gate opens, ions flow in, and the neuron becomes more active. NMDA receptors are deeply involved in learning, memory formation, pain signaling, and the kind of coordinated brain activity that produces conscious awareness of the world.
Ketamine and PCP block these receptors from the inside. The drug molecule slips into the open channel and physically plugs it, preventing ions from flowing through. At a cellular level, ketamine reduces both how often the channel opens and how long it stays open when it does. At a concentration of one micromolar, ketamine cut channel opening frequency to about 44% of normal and mean open time to about 68% of normal in laboratory studies.2PubMed. Multiple mechanisms of ketamine blockade of N-methyl-D-aspartate receptors The result is a broad dampening of excitatory signaling across the brain, but not the uniform suppression you see with drugs like propofol or barbiturates. This selective, channel-dependent blockade is what gives dissociative anesthetics their distinctive profile.
There is an important wrinkle here. Although NMDA receptor blockade is unquestionably the primary mechanism, researchers have found that ketamine’s effects are not explained by that single target alone. Recent work has questioned whether NMDA blockade is even the critical factor behind some of ketamine’s more surprising actions, particularly its rapid antidepressant effects.3PubMed Central. Ketamine: NMDA Receptors and Beyond The drug also interacts with other molecular targets in the brain, which partly explains why it does things that no other NMDA blocker can replicate.
Beyond the NMDA Receptor
One of the more striking discoveries in recent years is that ketamine also inhibits a type of ion channel called HCN1. These channels generate a pacemaker current in neurons that helps set the electrical rhythm of brain circuits. In studies using mice that lacked HCN1 channels, ketamine’s ability to produce a hypnotic state was substantially weakened, suggesting that blocking this channel plays a genuine role in making people lose consciousness.4PubMed Central. HCN1 channel subunits are a molecular substrate for hypnotic actions of ketamine Follow-up experiments showed that HCN1 channels specifically in the forebrain are a relevant target. Ketamine’s inhibition of these channels shifts the electrical properties of cortical neurons in a way that contributes to the drug’s sedative and hypnotic effects.5PubMed Central. Forebrain HCN1 channels contribute to hypnotic actions of ketamine
This multi-target pharmacology is part of what makes dissociative anesthetics so different from other drugs that simply turn the brain’s volume down. Ketamine is simultaneously blocking excitatory glutamate signals through NMDA receptors, altering pacemaker rhythms through HCN1 channels, and affecting several other receptor systems at varying concentrations. The net effect is a state that is not quite unconsciousness in the way other anesthetics produce it and not quite wakefulness either.
What Dissociation Actually Looks Like in the Brain
Brain imaging and electrical recording studies paint a vivid picture of how dissociative anesthetics fragment normal brain communication. The default mode network, a set of brain regions active during self-reflection and mind-wandering, is particularly disrupted. Under ketamine, connectivity within this network drops, especially between the medial prefrontal cortex and the rest of the network. At the same time, the normal push-pull relationship between the default mode network and other brain regions breaks down.6PubMed. Resting-state Network-specific Breakdown of Functional Connectivity during Ketamine Alteration of Consciousness in Volunteers
Ketamine also scrambles the salience network, which normally helps the brain decide what deserves attention. In healthy volunteers given a low dose of ketamine, researchers found that the drug produced frequency-dependent changes in connectivity within and between the default mode and salience networks, and these shifts correlated with symptoms of dissociation.7PubMed. Resting-state functional EEG connectivity in salience and default mode networks and their relationship to dissociative symptoms during NMDA receptor antagonism In plainer terms, the brain’s systems for self-awareness and for deciding what matters are both knocked out of their usual coordination. This is probably why people under dissociative anesthesia can have their eyes open, respond to some stimuli, and yet have no integrated experience of what is happening around them.
At the level of sensory processing, ketamine disrupts the transfer of perceptual information between the thalamus (the brain’s relay station for sensory input) and the cortex. This interference occurs across a broad range of frequencies, effectively cutting the line between raw sensory data and the cortical areas that would normally make sense of it.8PubMed Central. The psychotomimetic ketamine disrupts the transfer of late sensory information in the corticothalamic network
A Distinctive Electrical Signature
Electroencephalogram (EEG) recordings under ketamine look nothing like those under conventional anesthetics. Ketamine produces a characteristic pattern: slow-wave activity in the delta and theta bands drops, alpha rhythms decrease, and fast gamma oscillations surge.9PubMed Central. Effects of Ketamine on Resting-State EEG Activity and Their Relationship to Perceptual/Dissociative Symptoms in Healthy Humans This is nearly the opposite of what happens under propofol or sevoflurane, where slow waves dominate and fast activity is suppressed.
At high doses sufficient to produce full unconsciousness, ketamine generates gamma oscillations above 25 Hz that are periodically interrupted by slow-delta oscillations between 0.1 and 4 Hz. Computational modeling suggests that this oscillatory pattern emerges directly from the kinetics of NMDA receptor blockade: as the drug cycles between blocking and unblocking channels, the network alternates between bursts of fast activity and slow pauses.10PubMed Central. Ketamine can produce oscillatory dynamics by engaging mechanisms dependent on the kinetics of NMDA receptors This distinctive EEG pattern is one reason standard depth-of-anesthesia monitors, which were designed for conventional anesthetics, give unreliable readings during ketamine anesthesia.
Why Breathing and Blood Pressure Are Preserved
The single most clinically important feature of dissociative anesthetics is that they keep patients breathing. Nearly every other class of general anesthetic suppresses respiratory drive: opioids slow it, propofol can stop it, and benzodiazepines dampen it. Ketamine does the opposite. Compared to propofol, ketamine anesthesia is associated with increased breathing rate, larger breath volumes, and stronger activity in the muscles that keep the upper airway open. The genioglossus muscle, the main tongue muscle responsible for preventing airway collapse, actually becomes more active with increasing ketamine dose, whereas propofol suppresses it in a dose-dependent way.11PubMed Central. Ketamine Activates Breathing and Abolishes the Coupling between Loss of Consciousness and Upper Airway Dilator Muscle Dysfunction
Ketamine also stimulates the cardiovascular system. It increases heart rate and blood pressure through sympathomimetic activity, meaning it triggers the release of stress hormones like norepinephrine. Even the newer formulation, esketamine (the S-enantiomer), preserves the body’s normal breathing response to low oxygen while raising heart rate and blood pressure.12PubMed. Neuroanatomical and pharmaco-physiological effects of hypoxia and esketamine on breathing, the sympathetic nerve system, and cortical function This combination of maintained airway reflexes and cardiovascular support is why ketamine is the anesthetic of choice in situations where other drugs would be dangerous.
Where Dissociative Anesthetics Are Used Clinically
Emergency and trauma medicine is where ketamine’s unique safety profile matters most. In patients with burns, hemorrhagic shock, or unstable blood pressure, the sympathomimetic effects help maintain cardiovascular tone and organ perfusion. Comparative studies indicate that ketamine maintains hemodynamic stability better than etomidate and has a more favorable respiratory profile than benzodiazepine-opioid combinations.13PubMed Central. Ketamine Use for ED Sedation: Pharmacologic Basis, Clinical Applications, and Safety Considerations Emergency departments also use it heavily for procedural sedation in children, where brief painful procedures like fracture reduction or wound repair need a fast-acting drug that does not require intubation.
Pain management is another major application. Because NMDA receptors are involved in a phenomenon called central sensitization, where the spinal cord amplifies pain signals, ketamine at doses well below anesthetic levels can be a powerful analgesic. It is particularly useful for a paradoxical condition called opioid-induced hyperalgesia, where prolonged opioid use actually increases pain sensitivity. Blocking NMDA receptors with ketamine can restore normal pain processing. In one reported case, a three-day ketamine infusion after total cessation of opioids allowed a patient to recover from severe hyperalgesia, with pain subsequently well-controlled by standard opioid doses.14Pain Management Case Reports. Perioperative Ketamine Infusion is Effective in Reversing Opioid-Induced Hyperalgesia
The Antidepressant Surprise
Perhaps the most unexpected chapter in dissociative anesthetic pharmacology began when researchers noticed that a single low dose of ketamine could relieve depression within hours, even in patients who had not responded to conventional antidepressants. Standard antidepressants typically take weeks to work and fail roughly a third of the time. Ketamine’s rapid action was so unusual that it launched an entirely new area of psychiatric research.15Neuropharmacology. Signaling pathways underlying the rapid antidepressant actions of ketamine
The mechanism appears to involve a cascade that starts with NMDA blockade but goes far beyond it. Animal and human studies suggest that the initial receptor blockade triggers a burst of glutamate activity that, paradoxically, leads to new synapse formation, particularly in the prefrontal cortex. This synaptogenesis reverses some of the structural damage caused by chronic stress and depression, where neurons lose spines and connections. The result is a rapid functional reconnection of prefrontal circuits.16PubMed Central. Ketamine’s Mechanism of Action: A Path to Rapid-Acting Antidepressants This discovery led to the FDA approval of esketamine nasal spray for treatment-resistant depression in 2019, making it the first fundamentally new mechanism for treating depression in decades.
The Subjective Experience
What does being on a dissociative anesthetic actually feel like? At low, sub-anesthetic doses, users describe a range of perceptual changes. In a study examining the phenomenology of ketamine experiences, the most commonly reported appealing effects were “melting into the surrounding,” visual hallucinations, out-of-body experiences, and a feeling of “giggliness.” About two-thirds of users rated these as the most attractive features.17PubMed. Journey through the K-hole: phenomenological aspects of ketamine use At higher doses, the experience deepens into what recreational users call a “K-hole,” a state of profound detachment from the body and environment that can include mystical or terrifying experiences. From a clinical perspective, this subjective phenomenology maps onto the network disruption described above: the collapse of self-referential processing in the default mode network and the severing of normal thalamocortical communication.
The dissociative state also differs from classic psychedelic experiences produced by drugs like LSD or psilocybin. Classic psychedelics primarily activate serotonin 5-HT2A receptors and tend to inhibit both principal neurons and interneurons across the brain. Dissociative anesthetics, by blocking NMDA receptors, produce a more mixed pattern, inhibiting principal cells but exciting interneurons in many brain regions.18bioRxiv. Classic and dissociative psychedelics induce similar hyper-synchronous states in the cognitive-limbic cortex-basal ganglia system This pharmacological difference produces a qualitatively different experience: where classic psychedelics often intensify perception and emotion, dissociatives tend to detach the user from both.
Risks and Side Effects
Short-term side effects of dissociative anesthetics include nausea, elevated blood pressure, vivid dreams or hallucinations during emergence, and temporary confusion. These are generally manageable in clinical settings. The more serious concerns involve repeated or heavy use.
One of the best-documented harms of chronic ketamine use is bladder damage. Ketamine and its metabolites pass through the urinary tract and can cause severe inflammation of the bladder lining, leading to a condition sometimes called ketamine-induced cystitis. The damage includes destruction of the protective urothelial barrier, blood vessel changes, increased oxidative stress, and eventually bladder wall fibrosis. In severe cases, continued abuse can lead to ureteral strictures, hydronephrosis, and kidney failure.19PubMed Central. Pathophysiology, clinical presentation, and management of ketamine-induced cystitis The precise mechanism is still being worked out, but it appears that the presence of ketamine and its breakdown products in urine directly damages the bladder epithelium.20PubMed Central. Ketamine-Induced Cystitis: A Comprehensive Review of the Urologic Effects of This Psychoactive Drug
Neurotoxicity is another area of concern, though the picture is more nuanced than headlines sometimes suggest. In rat models, high doses of NMDA antagonists can produce a type of brain damage called Olney’s lesions, characterized by abnormal vacuoles forming inside neurons, followed by neuronal death in specific brain regions, particularly the retrosplenial cortex.21Neurotoxicology and Teratology. A comparison of the pharmacokinetics and NMDAR antagonism-associated neurotoxicity of ketamine, (2R,6R)-hydroxynorketamine and MK-801 However, the doses needed to produce these lesions in rats are far above typical clinical doses. In a recent comparative study, neuronal damage from ketamine appeared only at the highest dose tested (100 mg/kg), only in adult female rats, and affected fewer than a quarter of neurons in the affected region in just 3 out of 12 animals.22PubMed Central. The Comparative Sensitivity to Ketamine-Induced Neuronal Death in Juvenile and Adult Rats Whether any similar process occurs in humans at clinical doses remains unresolved.
The cognitive effects of chronic recreational ketamine use present a complicated picture. Acute doses reliably produce temporary impairments in memory, attention, and thinking speed. Among heavy long-term users, some studies report persistent deficits in verbal memory, working memory, and visual recognition even after periods of abstinence, while others suggest partial recovery or minimal lasting damage depending on how much and how often the person used.23PubMed Central. Controversies of the Effect of Ketamine on Cognition The presence of other drug use in these populations makes it hard to isolate ketamine’s specific contribution.
Veterinary Applications
Ketamine is arguably even more important in veterinary medicine than in human medicine. Its ability to maintain breathing and cardiovascular stability makes it invaluable for species where intubation is difficult or where field conditions rule out sophisticated monitoring. Tiletamine, another dissociative anesthetic, is commonly combined with the sedative zolazepam and marketed under the brand name Telazol for veterinary use.
In large animal medicine, ketamine-based cocktails are standard for pigs and primates. A combination of tiletamine/zolazepam, ketamine, and the sedative dexmedetomidine provides effective general anesthesia in swine for procedures lasting 45 to 90 minutes, with induction taking about a minute and recovery occurring within 18 to 35 minutes.24PubMed Central. Tiletamine/Zolazepam and Ketamine with Dexmedetomidine (TKD) Cocktail Is as Effective as Tiletamine/Zolazepam and Ketamine with Xylazine (TKX) in Providing Pig General Anesthesia In baboons undergoing laparoscopic surgery, a medetomidine-ketamine protocol produced greater cardiorespiratory stability than a tiletamine-zolazepam protocol, with lower rates of dangerously low blood pressure (about 6% versus 46%).25PubMed Central. Comparison of Cardiorespiratory Effects of Two Balanced Anesthesia Protocols in Baboons (Papio hamadryas) Undergoing Laparoscopic Salpingectomy These protocols illustrate a broader principle: in veterinary practice, ketamine is almost always combined with other drugs that smooth out its stimulatory effects while preserving its safety advantages.
Designer Dissociatives and Illicit Analogs
The basic chemical scaffold of PCP has proven easy to modify, and a growing number of designer dissociatives have appeared on illicit markets. Compounds like 3-MeO-PCP and 4-MeO-PCP are methoxy-substituted variants of phencyclidine that retain NMDA receptor affinity while differing in potency and side-effect profile. Both are predicted to cross the blood-brain barrier easily, bind extensively to plasma proteins, and distribute widely through body tissues.26PubMed. ADME profile of phencyclidine (PCP) analogues: emerging dissociative hallucinogens 3-MeO-PCP and 4-MeO-PCP
Another analog, 3-MeO-PCMo, has moderate affinity for the NMDA receptor comparable to ketamine itself, with roughly twelve-fold lower affinity than PCP.27PubMed. Syntheses, analytical and pharmacological characterizations of the ‘legal high’ 4-[1-(3-methoxyphenyl)cyclohexyl]morpholine (3-MeO-PCMo) and analogues Animal studies show these compounds activate the brain’s reward circuitry. Both 4-MeO-PCP and 3-MeO-PCMo produce rewarding and reinforcing effects in animals through activation of the mesolimbic dopamine pathway, and these effects can be blocked by dopamine receptor antagonists.28PubMed. 4-MeO-PCP and 3-MeO-PCMo, new dissociative drugs, produce rewarding and reinforcing effects through activation of mesolimbic dopamine pathway That dopamine involvement is relevant because it is the same reward circuit implicated in the addictive potential of ketamine itself, where dopamine release and changes in neural plasticity in reward areas remain a concern as clinical ketamine use expands.29PubMed Central. A short burst of reward curbs the addictiveness of ketamine
The proliferation of these analogs poses a real challenge for emergency physicians and forensic toxicologists. Standard drug screens often do not detect newer dissociatives, and their pharmacology can differ from ketamine or PCP in unpredictable ways, with some carrying a higher theoretical risk of producing toxic metabolites during breakdown in the body.26PubMed. ADME profile of phencyclidine (PCP) analogues: emerging dissociative hallucinogens 3-MeO-PCP and 4-MeO-PCP Anyone encountering an unfamiliar dissociative substance should treat it as a medical emergency, since the margin between a psychoactive dose and a dangerous one can be razor-thin with these unregulated compounds.